CureVac NV (5CV)

Frankfurt
Currency in EUR
2.88
+0.04(+1.41%)
Closed·
5CV Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
2.732.88
52 wk Range
2.144.95
Key Statistics
Edit
Bid/Ask
2.82 / 2.94
Prev. Close
2.88
Open
2.84
Day's Range
2.73-2.88
52 wk Range
2.14-4.95
Volume
7.42K
Average Volume (3m)
17.27K
1-Year Change
27.1%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
5CV Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Valuation implies a strong free cash flow yield
Show more

CureVac NV Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). The company’s portfolio includes clinical and preclinical candidates for various disease indications in prophylactic vaccines, oncology, and molecular therapy. It also delivers optimized mRNAs to stimulate the production of therapeutic proteins utilizing its technology instructs human cells to produce or secrete specific proteins in the nucleus, cytoplasm, cellular organelles, and cell membrane. In addition, the company offers The RNA Printer, a downsized, integrated, and highly automated process for manufacturing of mRNA vaccines and therapeutics. Further, it develops prophylactic vaccine lead candidate that addresses urinary tract infections targeting uropathogenic E. coli (UPEC) bacteria; vaccine candidates CV0601 and CV0701, which are in phase 2 clinical study against SARS-CoV-2; vaccines for off-the-shelf and fully personalized cancer precision immunotherapies in oncology; and CVGBM for treating cancer. Additionally, the company develops, manufactures, and commercializes mRNA vaccines targeting SARS-CoV-2 variants; antigen cancer precision immunotherapy candidate that targets squamous non-small cell lung cancer; and antigen cancer precision immunotherapy candidate CVGBM that is tested in patients with surgically resected MGMT-unmethylated glioblastoma or astrocytoma with a molecular signature of glioblastoma. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Compare 5CV to Peers and Sector

Metrics to compare
5CV
Peers
Sector
Relationship
P/E Ratio
3.9x−2.5x−0.5x
PEG Ratio
0.020.140.00
Price/Book
0.9x1.1x2.6x
Price / LTM Sales
1.2x5.3x2.9x
Upside (Analyst Target)
-92.6%58.9%
Fair Value Upside
Unlock−3.8%8.0%Unlock

Earnings

Latest Release
Apr 10, 2025
EPS / Forecast
-0.16 / -0.245
Revenue / Forecast
14.50M / 8.91M
EPS Revisions
Last 90 days

People Also Watch

7.350
QBTS
+3.09%
2.910
BBAI
+7.78%
6.9400
QUBT
+8.95%
9.300
RGTI
+2.09%
120.54
BNTX
+4.97%

FAQ

What Is the CureVac NV (5CV) Stock Price Today?

The CureVac NV stock price today is 2.88

What Stock Exchange Does CureVac NV Trade On?

CureVac NV is listed and trades on the Frankfurt stock exchange.

What Is the Stock Symbol for CureVac NV?

The stock symbol for CureVac NV is "5CV."

What Is the CureVac NV Market Cap?

As of today, CureVac NV market cap is 646.81M.

What is CureVac NV Earnings Per Share?

The CureVac NV EPS is 0.72.

What Is the Next CureVac NV Earnings Date?

CureVac NV will release its next earnings report on May 20, 2025.

From a Technical Analysis Perspective, Is 5CV a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.